Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Rhea-AI Summary
Immutep (NASDAQ: IMMP) announced an abstract has been accepted for poster presentation at the ASCO 2026 Annual Meeting in Chicago, 29 May–2 June 2026. The poster, titled “Impact of eftilagimod alfa…on lymphocyte activation and survival outcomes in metastatic cancer patients,” is scheduled for 30 May 2026, 1:30 PM–4:30 PM CDT, Poster Board 359, Abstract #2569.
The presentation will report cumulative clinical and translational data across multiple late-stage cancer studies indicating that eftilagimod alfa (efti), an APC activator via MHC class II, induces rapid and sustained lymphocyte activation associated with improved overall survival in metastatic patients.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – IMMP
On the day this news was published, IMMP declined 4.76%, reflecting a moderate negative market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $82.78M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IMMP fell 4.3% while key biotech peers ACIU (-5.28%), CADL (-3.98%), EDIT (-8.08%), FENC (-2.97%) and HUMA (-3.82%) also traded lower, indicating broader sector weakness alongside the ASCO abstract news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 15 | Orphan designation win | Positive | +72.8% | FDA Orphan Drug Designation for efti in soft tissue sarcoma. |
| Mar 19 | Phase I progress | Positive | -0.7% | Successful SAD completion and MAD progression for IMP761 in Phase I. |
| Mar 13 | Phase III futility stop | Negative | -82.4% | TACTI-004 Phase III NSCLC study discontinued after futility analysis. |
| Feb 06 | Phase III enrolment | Neutral | +0.0% | TACTI-004 Phase III trial reached 50% enrolment and futility remains on track. |
| Jan 29 | Quarterly update | Positive | -2.9% | Quarterly report with major efti licensing deal and extended cash runway. |
Recent news has produced mixed reactions: major positive regulatory and clinical updates drove sharp gains, while operational and trial progress updates often saw flat or negative moves.
Over the past six months, Immutep has reported multiple clinical and regulatory milestones around eftilagimod alfa and IMP761. A March 13, 2026 futility-driven discontinuation of the TACTI-004 Phase III NSCLC study led to a sharp -82.44% move. In contrast, FDA Orphan Drug Designation for efti in soft tissue sarcoma on April 15, 2026 saw a strong 72.81% gain. Earlier, Phase I progress for IMP761 and TACTI-004 enrolment updates produced minimal or negative price reactions, showing investors react most strongly to pivotal trial and designation outcomes.
Market Pulse Summary
This announcement highlights acceptance of an ASCO 2026 poster presenting cumulative data for eftilagimod alfa on lymphocyte activation and survival in metastatic cancer. It underscores ongoing clinical interest in the drug’s mechanism as an antigen-presenting cell activator targeting MHC Class II. In light of prior Orphan Drug Designation and mixed trial outcomes, investors may watch for detailed efficacy, safety, and survival metrics from this presentation and subsequent late-stage studies.
Key Terms
immunotherapy medical
antigen-presenting cell medical
apc activator medical
mhc class ii medical
lymphocyte medical
metastatic medical
overall survival medical
AI-generated analysis. Not financial advice.
SYDNEY, AUSTRALIA, April 22, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an abstract has been selected for poster presentation at the upcoming 2026 American Society of Clinical Oncology’s (ASCO) Annual Meeting, taking place in-person and online from 29 May-2 June 2026 in Chicago, Illinois (United States).
The accepted abstract, titled “Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients,” will be presented within the Developmental Therapeutics—Immunotherapy sessions by Professor Martin Forster from the UCL Cancer Institute, UK.
The poster will present cumulative clinical and translational data demonstrating that eftilagimod alfa (efti), an antigen-presenting cell (APC) activator targeting MHC Class II, induces rapid and sustained lymphocyte activation. Across multiple late-stage cancer studies1, immune activation markers were associated with improved overall survival outcomes in patients with metastatic disease, supporting the clinical relevance of eftilagimod alfa’s mechanism of action.
ASCO 2026 Poster Presentation Details
Title: Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients
Poster Session: Developmental Therapeutics—Immunotherapy
Date and Time: 30 May 2026, 1:30 PM-4:30 PM CDT
Poster Board: 359
Abstract #: 2569
About ASCO 2026
The ASCO Annual Meeting represents the world’s largest gathering of oncology physicians, industry representatives, researchers, patient advocates and investment analysts to discuss cutting-edge clinical research and emerging therapeutics in oncology, and to gain insights to improve cancer care. More than 40,000 attendees from around the world are expected to participate in person and online to stay up to date on the latest advances across all areas of cancer research and to hear real-time insights from world-renowned experts. For additional information on the ASCO Annual Meeting, please visit www.asco.org.
About Immutep
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com
U.S. Investors/Media:
Matthew Beck, astr partners
+1 (917) 415-1750; matthew.beck@astrpartners.com
This announcement was authorised for release by the CEO of Immutep Limited.
1 Please note that the abstract does not include data from the TACTI-004 study, as immune data collection for that trial has not yet been completed. All data presented were collected from earlier clinical trials, initiated prior to TACTI-004.
